Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lawson, Kim (2016)
Publisher: Informa Healthcare
Languages: English
Types: Article
INTRODUCTION: \ud \ud Fibromyalgia (FM) is a common, complex chronic widespread pain condition is characterized by fatigue, sleep disturbance and cognitive dysfunction. Treatment of FM is difficult, requiring both pharmacological and non-pharmacological approaches, with an empiric approach to drug therapy focused toward individual symptoms, particularly pain. The effectiveness of current medications is limited with many patients discontinuing use.\ud \ud AREAS COVERED: \ud \ud A systemic database search has identified 26 molecular entities as potential emerging drug therapies. Advances in the understanding of the pathophysiology of FM provides clues to targets for new medications. Investigation of bioamine modulation and α2δ ligands and novel targets such as dopamine receptors, NMDA receptors, cannabinoid receptors, melatonin receptors and potassium channels has identified potential drug therapies.\ud \ud EXPERT OPINION: \ud \ud Modest improvement of health status in patients with FM has been observed with drugs targeting a diverse range of molecular mechanisms. No single drug, however, offered substantial efficacy against all the symptoms characteristic of FM. Identification of new and improved therapies for FM needs to address the heterogeneity of the condition, which suggests existence of patient subgroups, the relationship of central and peripheral aspects of the pathophysiology and a requirement of combination therapy with drugs targeting multiple molecular mechanisms.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. 2008;37(6):339-52.
    • 2. Yunus MB. Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology. Curr Rheumatol Rev. 2015;11(2):70-85.
    • 3. Häuser W, Ablin J, Fitzcharles MA, et al. Fibromyalgia. Nat Rev Dis Primers 2015;1:15022.
    • 4. Borchers AT, Gershwin ME. Fibromyalgia: A Critical and Comprehensive Review. Clin Rev Allergy Immunol. 2015;49(2):100-51. **Provides a comprehensive review of current knowledge of the pathophysiology of fibromyalgia.
    • 5. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat. 2008;4(6):1059-71.
    • 6. Glass JM. Fibromyalgia and cognition. J Clin Psychiatry. 2008;69 Suppl 2:20-4.
    • 7. Bertolucci PH, de Oliveira FF Cognitive impairment in fibromyalgia. Curr Pain Headache Rep. 2013 Jul;17(7):344.
    • 8. Ceko M, Bushnell MC, Gracely RH. Neurobiology underlying fibromyalgia symptoms. Pain Res Treat. 2012;2012:585419.
    • 9. Williams DA, Clauw DJ. Understanding Fibromyalgia: Lessons from the Broader Pain Research Community. J Pain. 2009;10(8):777-791.
    • 10. Chin S, Caldwell W, Gritsenko, K. Fibromyalgia Pathogenesis and Treatment Options Update. Curr Pain Headache Rep. 2016;20:25.
    • 11. Üçeyler N, Zeller D, Kahn AK, et al. Small fibre pathology in patients with fibromyalgia syndrome. Brain. 2013;136:1857-67.
    • 12. Caro XJ, Winter EF. The Role and Importance of Small Fiber Neuropathy in Fibromyalgia Pain. Curr Pain Headache Rep. 2015;19(12):55.
    • 13. Albrecht PJ, Hou Q, Argoff CE, et al. Excessive peptidergic sensory innervation of cutaneous arteriole-venule shunts (AVS) in the palmar glabrous skin of fibromyalgia patients: implications for widespread deep tissue pain and fatigue. Pain Med. 2013;14(6):895-915.
    • 14. Harris RE, Clauw DJ. How do we know that the pain in fibromyalgia is "real"? Curr Pain Headache Rep. 2006;10(6):403-7.
    • 15. Laske C, Stransky E, Eschweiler GW, et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res. 2007;41(7):600-5.
    • 16. Harris RE, Sundgren PC, Craig AD, et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum. 2009;60(10):3146-52.
    • 17. Abeles AM, Pillinger MH, Solitar BM, et al. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med. 2007;146(10):726-34.
    • 18. Ablin JN, Buskila D, Clauw DJ. Biomarkers in fibromyalgia. Curr Pain Headache Rep. 2009;13(5):343-9.
    • 19. Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25(12):3576-82.
    • 20. Wood PB, Holman AJ. An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol. 2009;36(2):221-4.
    • 21. Guedj E, Cammilleri S, Niboyet J, et al. Clinical correlate of brain SPECT perfusion abnormalities in fibromyalgia. J Nucl Med. 2008;49(11):1798-803.
    • 22. Adigüzel O, Kaptanoglu E, Turgut B, et al. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. South Med J. 2004;97(7):651-5.
    • 23. Ablin JN, Buskila D. Update on the genetics of the fibromyalgia syndrome. Best Pract Res Clin Rheumatol. 2015;29(1):20-8.
    • 24. Becker S, Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat. 2012;2012:741746.
    • 25. Macedo JA, Hesse J, Turner JD, et al. Glucocorticoid sensitivity in fibromyalgia patients: decreased expression of corticosteroid receptors and glucocorticoidinduced leucine zipper. Psychoneuroendocrinology. 2008;33(6):799-809.
    • 26. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6-21.
    • 27. Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry. 2008;69 Suppl 2:6-13.
    • 28. Gur A, Oktayoglu P. Status of immune mediators in fibromyalgia. Curr Pain Headache Rep. 2008;12(3):175-81.
    • 29. Cassisi G, Sarzi-Puttini P, Casale R, et al. Pain in fibromyalgia and related conditions. Reumatismo. 2014;66(1):72-86.
    • 30. Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16(1):201.
    • 31. Kim SC, Landon JE, Lee YC. Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia. Arthritis Res Ther. 2015;17:18.
    • 32. Häuser W, Jung E, Erbslöh-Möller B, et al. The German fibromyalgia consumer reports - a cross-sectional survey. BMC Musculoskelet Disord. 2012;13:74.
    • 33. Wolfe F, Walitt BT, Katz RS, et al. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;17(4):581-6.
    • 34. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51(1):9-13.
    • 35. Moldofsky H, Harris HW, Archambault WT, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011;38(12):2653-63.
    • 36. Lederman S, Clauw D, Gendreau J, et al. TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization Ann Rheum Dis 2015;74:313. *Efficacy data on sublingual formulation of very low dose cyclobenzaprine.
    • 38. Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120(5):448-54.
    • 39. Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, et al. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010;11:204.
    • 40. Calandre EP, Morillas-Arques P, Molina-Barea R, et al. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord. 2011;12:95.
    • 41. Inoue A, Hashimoto T, Hide I, et al. 5-Hydroxytryptamine-facilitated release of substance P from rat spinal cord slices is mediated by nitric oxide and cyclic GMP. J Neurochem. 1997;68(1):128-33.
    • 42. Färber L, Haus U, Späth M, Drechsler S. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl. 2004;119:2-8.
    • 43. Vergne-Salle P, Dufauret-Lombard C, Bonnet C, et al. A randomised, doubleblind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. Eur J Pain. 2011;15(5):509-14.
    • 44. Yeephu S, Suthisisang C, Suttiruksa S et al. Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study. Ann Pharmacother. 2013;47(7-8):921-32.
    • 45. Arnold LM, Hirsch I, Sanders P, et al. Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebocontrolled, multicenter clinical trial. Arthritis Rheum. 2012;64(7):2387-97.
    • 48. Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25(12):3576-82.
    • 49. Ledermann K, Jenewein J, Sprott H, et al. Relation of dopamine receptor 2 binding to pain perception in female fibromyalgia patients with and without depression - A [(11)C] raclopride PET-study. Eur Neuropsychopharmacol. 2016;26(2):320-30.
    • 50. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52(8):2495-505.
    • 51. Holman AJ. Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia. J Clin Rheumatol. 2003;9(4):277-9.
    • 52. Distler O, Eich W, Dokoupilova E, et al. Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2010 Jan;62(1):291-300.
    • 53. Palangio M, Flores JA, Joyal SV. Treatment of fibromyalgia with sibutramine hydrochloride monohydrate: comment on the article by Goldenberg et al. Arthritis Rheum. 2002;46(9):2545-6.
    • 54. Wittkampf LC, Arends J, Timmerman L, Lancel M. A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia. Ther Adv Psychopharmacol. 2012;2(3):115-25.
    • 55. Schwartz TL, Siddiqui UA, Raza S, Morell M. Armodafinil for fibromyalgia fatigue. Ann Pharmacother. 2010;44(7-8):1347-8.
    • 56. Katz RS, Bond H, Leavitt F. Methylphenidate improves concentration, energy and mood in fibromyalgia. Arthritis Rheum 2013;65(Suppl):S470.
    • 57. Ramzy EA. Comparative Efficacy of Newer Antidepressants in Combination with Pregabalin for Fibromyalgia Syndrome: A Controlled, Randomized Study. Pain Pract. 2016;doi: 10.1111/papr.12409. *Peer reviewed efficacy data of antidepressants and α2δ ligand combination therapies.
    • 58. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev. 2013;8:CD004844.
    • 59. Potvin S, Morin M, Cloutier C, et al. Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol. 2012;32(5):684-7.
    • 60. McIntyre A, Paisley D, Kouassi E, Gendron A. Quetiapine fumarate extendedrelease for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. Arthritis Rheumatol. 2014;66(2):451-61
    • 61. Calandre EP, Rico-Villademoros F, Galán J, et al. Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: a 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology (Berl). 2014;231(12):2525-31.
    • 65. Calandre EP, Hidalgo J, Rico-Villademoros F. Use of ziprasidone in patients with fibromyalgia: a case series. Rheumatol Int. 2007;27(5):473-6.
    • 66. Yokoyama T, Arakawa N, Domon Y, et al. Pharmacological, pharmacokinetics and safety profiles of DS-5565 a novel a2α ligand. Poster presented at the World Congress of Neurology, Vienna, Austria, 21-26 September 2013.
    • 67. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 2006;103:17537- 42.
    • 68. Treatment of Pain Associated With Fibromyalgia https://clinicaltrials.gov/ct2/show/NCT02146430. [Last accessed 4 March 2016].
    • 69. Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat 2009;5:467-76.
    • 70. Chong MS, Libretto SE. The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 2003;19(1):59-68.
    • 73.Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev. 2013;10:CD010782.
    • 108. Sources of information, Medline(Pubmed), ClinicalTrials.gov, adisinsight.springer.com and Controlled-trials.com.
    • 109. FIQ - fibromyalgia impact questionnaire;
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article